Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma

被引:40
|
作者
Cui, Wenli [1 ,2 ,3 ,4 ]
Cai, Ying [1 ,2 ,3 ]
Wang, Weige [1 ,2 ,3 ]
Liu, Zebing [1 ,2 ,3 ]
Wei, Ping [1 ,2 ,3 ]
Bi, Rui [1 ,2 ,3 ]
Chen, Weixiang [1 ,2 ,3 ]
Sun, Menghong [1 ,2 ,3 ]
Zhou, Xiaoyan [1 ,2 ,3 ]
机构
[1] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai 200032, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China
[3] Fudan Univ, Inst Pathol, Shanghai 200032, Peoples R China
[4] Xinjiang Med Univ, Affiliated Hosp 1, Dept Pathol, Urumqi 830054, Xinjiang Uygur, Peoples R China
关键词
DLBCL; CNV; PI3K/AKT; Subunits; Survival; INTEGRATIVE GENOMIC ANALYSIS; GENE-EXPRESSION; AKT; PIK3CA; GROWTH; ISOFORMS; ROLES;
D O I
10.1186/1479-5876-12-10
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: It has been reported that the PI3K/AKT signaling pathway is activated in diffuse large B-cell lymphoma (DLBCL), PI3K constitutive activation plays a crucial role in PI3K/AKT pathway. However, the copy number variations (CNVs) of PI3K subunits on gene level remain unknown in DLBCL. Therefore, the aim of the study is to investigate the CNV of PI3K subunits and their relationship with clinicopathological features exploring the possible mechanism underlying of PI3K activation in DLBCL. Methods: CNV of 12 genes in the PI3K/AKT pathway was detected by NanoString nCounter in 60 de novo DLBCLs and 10 reactive hyperplasia specimens as controls. Meanwhile, immunohistochemistry (IHC) was performed to examine the expression of p110 alpha, p110 beta, p110 gamma, p110 delta, and pAKT on DLBCL tissue microarrays. Results: All PI3K and AKT subunits, except for PIK3R1, had various CNVs in the form of copy number amplifications and copy number losses. Their rates were in the range of 8.3-20.0%. Of them PIK3CA and PIK3CB gene CNVs were significantly associated with decreased overall survival (P = 0.029 and P = 0.019, respectively). IHC showed that the frequency of strong positive expression of p110 alpha, p110 beta, p110 gamma, and p110 delta were 26.7%, 25.0%, 18.3%, and 25.0% respectively, and they were found to be associated with decreased survival (P = 0.022, P = 0.015, P = 0.015, and P = 0.008, respectively). Expression of p110 alpha was not only significantly associated with CNVs of PIK3CA (P = 0.002) but also positively correlated with strong positive expression of pAKT (P = 0.026). Conclusions: CNV of PIK3CA is highly associated with aberrant p110a protein expression and subsequent activation of PI3K/AKT pathway. CNVs of PIK3CA and PIK3CB, and aberrant protein expression of p110 isoforms are of great important value for predicting inferior prognosis in DLBCL. Frequent CNVs of PI3K/AKT subunits may play an important role in the tumorigenesis of DLBCL.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Targeting PI3K/AKT signaling pathway in obesity
    Savova, Martina S.
    Mihaylova, Liliya, V
    Tews, Daniel
    Wabitsch, Martin
    Georgiev, Milen I.
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 159
  • [22] The effects of Ginsenosides on PI3K/AKT signaling pathway
    Ghafouri-Fard, Soudeh
    Balaei, Neda
    Shoorei, Hamed
    Hasan, Syed Muhammad Farid
    Hussen, Bashdar Mahmud
    Talebi, Seyedeh Fahimeh
    Taheri, Mohammad
    Ayatollahi, Seyed Abdulmajid
    MOLECULAR BIOLOGY REPORTS, 2022, 49 (07) : 6701 - 6716
  • [23] The effects of Ginsenosides on PI3K/AKT signaling pathway
    Soudeh Ghafouri-Fard
    Neda Balaei
    Hamed Shoorei
    Syed Muhammad Farid Hasan
    Bashdar Mahmud Hussen
    Seyedeh Fahimeh Talebi
    Mohammad Taheri
    Seyed Abdulmajid Ayatollahi
    Molecular Biology Reports, 2022, 49 : 6701 - 6716
  • [24] Activation of the PI3K/Akt pathway and chemotherapeutic resistance
    West, KA
    Castillo, SS
    Dennis, PA
    DRUG RESISTANCE UPDATES, 2002, 5 (06) : 234 - 248
  • [25] PI3k/AKT signaling pathway: Erythropoiesis and beyond
    Jafari, Mahjoobeh
    Ghadami, Elham
    Dadkhah, Tahereh
    Akhavan-Niaki, Haleh
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (03) : 2373 - 2385
  • [26] The PI3K/Akt Pathway in Meta-Inflammation
    Acosta-Martinez, Maricedes
    Cabail, Maria Zulema
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (23)
  • [27] Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma
    Blachly, James S.
    Baiocchi, Robert A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 167 (01) : 19 - 32
  • [28] Multiple forms of cell death: A focus on the PI3K/AKT pathway
    Xu, Jiawei
    Li, Yu
    Kang, Meili
    Chang, Cuicui
    Wei, Hong
    Zhang, Chi
    Chen, Yuhua
    JOURNAL OF CELLULAR PHYSIOLOGY, 2023, 238 (09) : 2026 - 2038
  • [29] Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma
    Demicco, Elizabeth G.
    Torres, Keila E.
    Ghadimi, Markus P.
    Colombo, Chiara
    Bolshakov, Svetlana
    Hoffman, Aviad
    Peng, Tingsheng
    Bovee, Judith V. M. G.
    Wang, Wei-Lien
    Lev, Dina
    Lazar, Alexander J.
    MODERN PATHOLOGY, 2012, 25 (02) : 212 - 221
  • [30] Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3
    Yuan, Ting
    Zhang, Feng
    Zhou, Xiangxiang
    Li, Ying
    Zhang, Ya
    Xu, Yangyang
    Wang, Xin
    ONCOLOGY LETTERS, 2019, 17 (04) : 3719 - 3726